Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/182)
-
Patent number: 8663606Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: GrantFiled: October 21, 2011Date of Patent: March 4, 2014Assignee: Medigene AGInventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
-
Publication number: 20140057885Abstract: Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Applicant: SAGE THERAPEUTICS, INC.Inventors: Kiran Reddy, Stephen Jay Kanes
-
Publication number: 20140057884Abstract: A novel use of phytosterol isolated from Navicula incerta having effect of preventing or treating liver cancer is provided. Accordingly, a composition for preventing or treating liver cancer including stigmasterol and 5?-hydroxysitostanol isolated from Navicula incerta as an active ingredient is provided. Accordingly, and 5?-hydroxysitostano upregulate expression of genes involved with hepatoma cell apoptosis inducing factors, while downregulating genes involved with hepatoma cell apoptosis inhibiting genes, thereby lead into effective prevention or treatment of liver cancer.Type: ApplicationFiled: October 31, 2012Publication date: February 27, 2014Applicant: Pukyong National University Industry-University Cooperation FoundationInventors: Se-Kwon KIM, Kyong-Hwa KANG, Young-Sang KIM
-
Publication number: 20140056848Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.Type: ApplicationFiled: March 8, 2013Publication date: February 27, 2014Applicant: ENTREMED, INC.Inventors: Tak Wah Mak, Gordon Stuart Duncan
-
Publication number: 20140057886Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.Type: ApplicationFiled: August 28, 2013Publication date: February 27, 2014Applicant: INTERCEPT PHARMACEUTICALS, INC.Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
-
Patent number: 8658628Abstract: A hormone delivery system and method are provided for administering bio identical human hormones using a combination of modalities for the treatment of human physiological conditions.Type: GrantFiled: June 18, 2010Date of Patent: February 25, 2014Inventor: Karan Y. Baucom
-
Patent number: 8658629Abstract: A pharmaceutical composition for treating cachexia, and in particular for treating cancer cachexia. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.Type: GrantFiled: April 30, 2010Date of Patent: February 25, 2014Assignee: Sinphar Tian-Li Pharmaceutical Co., Ltd.Inventor: Hang-Ching Lin
-
Patent number: 8658630Abstract: The invention provides a means capable of effectively inactivating and removing allergen or a precursor thereof. The invention relates to an allergen-reducing agent containing water and a water-soluble polymer compound having units having hydroxy or carboxy groups wherein at least a part of hydrogen atoms of the hydroxy or carboxy groups are substituted by specific groups containing a polyether group.Type: GrantFiled: January 29, 2010Date of Patent: February 25, 2014Assignee: Kao CorporationInventors: Satoshi Nagai, Katsuyuki Takano, Masahiro Suzuki, Takeshi Ban, Michio Yokosuka, Takeshi Ihara, Tohru Nishioka
-
Publication number: 20140050791Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The inventions further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.Type: ApplicationFiled: November 30, 2011Publication date: February 20, 2014Applicant: DR. FALK PHARMA GMBHInventors: Rudolf Wilhelm, Markus Proels, Erik Fischer, Heidi Waenerlund Poulsen
-
Patent number: 8653057Abstract: Testosterone levels in a patient predicts whether or not the patient is likely to recover sexual potency following radical prostatectomy. Lower levels of testosterone are associated with a lower rate of potency recovery and with more aggressive prostate cancers. Therapeutically increasing circulating testosterone leads to improved rates of return to potency.Type: GrantFiled: July 29, 2011Date of Patent: February 18, 2014Assignee: The Regents of the University of CaliforniaInventors: Thomas E. Ahlering, Douglas Skarecky
-
Patent number: 8653056Abstract: The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is —OC—R—COOH, substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is —OC—R—COOH, quarternary ammonium substituents of general formula Xb bound to the carboxy group of the terpenoid, wherein Xb is —(CH2)nN+R3Y—, quarternary ammonium substituents of general formula Xc bound to the carboxy group of the terpenoid, wherein Xc je —(CH2)nR+Y—, substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents —R—COOH, glycosylic substituents Xe bound by alpha or beta glycosidic bond to the hydroxy group or to the carboxy group of the teType: GrantFiled: September 25, 2007Date of Patent: February 18, 2014Assignees: Univerzita Karlova V Praze, Prirodovedecka Fakulta, Univerzita Palackeho V Olomouci, I.Q.A., A.S.Inventors: Jan Sarek, Marian Hajduch, Michal Svoboda, Katerina Novakova, Pavla Spacilova, Tomas Kubelka, David Biedermann
-
Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
Patent number: 8653058Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.Type: GrantFiled: August 10, 2011Date of Patent: February 18, 2014Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert Emil Hodge, Jeffrey Douglas Webster, Robert M. Moriarty -
Publication number: 20140045805Abstract: This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and which affect mood in humans, to the incorporation of these 20-pregnene compounds into various compositions, and to methods of affecting the mood of individuals using such compounds.Type: ApplicationFiled: March 26, 2013Publication date: February 13, 2014Applicant: Human Pheromone Sciences, Inc.Inventor: Human Pheromone Sciences, Inc.
-
Publication number: 20140045807Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).Type: ApplicationFiled: November 1, 2012Publication date: February 13, 2014Inventors: Etienne-Emile BAULIEU, Ester Esther FELLOUS, Paul ROBEL, Massimiliano BIANCHI
-
Publication number: 20140044706Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.Type: ApplicationFiled: June 7, 2013Publication date: February 13, 2014Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
-
Publication number: 20140045808Abstract: A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.Type: ApplicationFiled: August 8, 2013Publication date: February 13, 2014Applicants: of Nevada, Las VegasInventors: Ernesto Abel-Santos, Amber Howerton
-
Patent number: 8647665Abstract: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: August 13, 2012Date of Patent: February 11, 2014Assignee: Antares Pharma IPL AGInventors: Stephen M. Simes, Leah M. Lehman
-
Publication number: 20140038932Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: ApplicationFiled: June 10, 2013Publication date: February 6, 2014Applicant: KYTHERA BIOPHARMACEUTICALS, INC.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Publication number: 20140038907Abstract: The present application teaches a coating having a biologically compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit and at least one unit derived from a vinyl alcohol, an allyl alcohol, or derivatives thereof.Type: ApplicationFiled: October 2, 2013Publication date: February 6, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Eugene T. Michal, Syed F.A. Hossainy, Ashok Shah
-
Publication number: 20140037743Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.Type: ApplicationFiled: October 11, 2013Publication date: February 6, 2014Applicant: DelivRx, Inc.Inventor: Daniel R. DeBrouse
-
Patent number: 8642567Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.Type: GrantFiled: November 10, 2009Date of Patent: February 4, 2014Assignee: The Hong Kong University of Science and TechnologyInventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
-
Publication number: 20140031326Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.Type: ApplicationFiled: November 17, 2011Publication date: January 30, 2014Applicant: WHITE MOUNTAIN PHARMA. INC.Inventors: Hillary D. White, Robert Gyurik
-
Publication number: 20140031327Abstract: The invention provides inhibitors of ?-crystallin aggregation and methods of using ?-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.Type: ApplicationFiled: July 17, 2013Publication date: January 30, 2014Applicant: REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Jason E. Gestwicki
-
Patent number: 8637474Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.Type: GrantFiled: January 5, 2012Date of Patent: January 28, 2014Assignee: The Hong Kong University of Science and TechnologyInventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
-
Publication number: 20140024632Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder. Accordingly, in one aspect, the present invention provides methods for treating patients with autism spectrum disorder. In one embodiment, a method for treating an autism spectrum disorder (ASD) in a patient comprises the step of administering a therapeutically effective amount of cholesterol to the patient. In more specific embodiments, the ASD is autism, Asperger's disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett's syndrome and childhood disintegrative disorder. In one embodiment, the patient has autism.Type: ApplicationFiled: July 18, 2013Publication date: January 23, 2014Inventors: Elaine Tierney, Forbes D. Porter
-
Publication number: 20140024630Abstract: The present invention refers to a method for the non-surgical treatment of a lypodistrophy caused by an antiretroviral therapy in an individual infected by a retrovirus, such as HIV, and undergoing said antiretroviral therapy said method comprising the step of administering an effective amount of a adipocitolytic composition comprising deoxycholic acid and/or a pharmaceutically acceptable salt thereof in a retrovirus-infected individual affected by said lipodistrophy.Type: ApplicationFiled: July 19, 2012Publication date: January 23, 2014Inventor: Raffaele RAUSO
-
Publication number: 20140024631Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: ApplicationFiled: February 7, 2013Publication date: January 23, 2014Applicant: INTERCEPT PHARMACEUTICALS, INC.Inventor: INTERCEPT PHARMACEUTICALS, INC.
-
Patent number: 8632763Abstract: The use of copolymers obtained by free-radical polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the total of components i), ii) and iii) equals 100% by weight, as solubilizers for slightly water-soluble substances.Type: GrantFiled: March 21, 2012Date of Patent: January 21, 2014Assignee: BASF SEInventors: Nathalie Bouillo, Marianna Pierobon, Ralf Widmaier, Rainer Dobrawa, Kathrin Meyer-Böhm, Ronald Frans-Maria Lange
-
Publication number: 20140017312Abstract: The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.Type: ApplicationFiled: September 19, 2013Publication date: January 16, 2014Applicant: Wyeth LLCInventors: William Bubnis, Richard Cotter, Paul W. Herman, Judith Moreines, Scott W. Poxon, Bruce W. Sutton, Jeffrey V. Vernon, Denise L. Walters, Michael G. Williams, Neil Wittenberg
-
Patent number: 8629130Abstract: A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general formula depicted below, herein R1, R2, R3, R4, R5, R6 and R7 are as defined herein.Type: GrantFiled: April 30, 2012Date of Patent: January 14, 2014Assignee: Endece, LLCInventor: James G. Yarger
-
Patent number: 8629129Abstract: Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.Type: GrantFiled: September 4, 2012Date of Patent: January 14, 2014Assignee: Endorecherche, Inc.Inventor: Fernand Labrie
-
Publication number: 20140011761Abstract: Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA) has been shown to reduce ER stress is TSC-deficient cells. Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide arid glycerol may also be useful in treating tuberous sclerosis. The present invention provides methods of treating a subject suffering from tuberous sclerosis using ER stress reducers such as PBA, TUDCA, UDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in TSC-deficient cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating tuberous sclerosis.Type: ApplicationFiled: December 20, 2012Publication date: January 9, 2014Applicant: President and Fellows of Harvard CollegeInventors: Gokhan S. Hotamisligil, Umut Ozcan, Brendan D. Manning
-
Publication number: 20140011791Abstract: Methods for effective remyelination in patients are disclosed comprising treating the patient with an androgen receptor ligand which exerts binding to androgen receptors and elicits androgen-receptor-induced biological responses at a dosage sufficient to induce remyelination. The androgen compound preferably comprises MENT in an androgen targeting both androgen and estrogen receptors, and the methods include combining the androgen compound with a progestin compound in order to provide both contraception in men and treatment for neurodegeneration.Type: ApplicationFiled: March 22, 2012Publication date: January 9, 2014Applicant: THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Abdelmouman Ghoumari, Said Ghandour, Rashad Hussain, Bartosz Bielecki
-
Publication number: 20140010806Abstract: The invention relates to methods to use 17?-ethynylandrost-5-ene-3?,7?,17?-triol to treat ocular diseases or conditions such as dry eye, uveitis or retinitis. The compound can be administered topically to the eye, by intravitreal injection or systemically, e.g., orally.Type: ApplicationFiled: March 15, 2013Publication date: January 9, 2014Inventors: James M. Frincke, Christopher L. Reading, Clarence N. Ahlem
-
Publication number: 20140010858Abstract: The present invention is directed to polymeric compositions comprising a biodegradable copolymer that possesses shape-memory properties and implantable devices (e.g., drug-delivery stents) formed of materials (e.g., a coating) containing such compositions. The polymeric compositions can also contain at least one non-fouling moiety, at least additional biocompatible polymer, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric compositions are formulated to possess good mechanical, physical and biological properties. Moreover, implantable devices formed of materials comprising such compositions can be delivered to the treatment site in a conveniently compressed size and then can expand to dimensions appropriate for their medical functions.Type: ApplicationFiled: May 28, 2013Publication date: January 9, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: John J. Stankus, O. Mikael Trollsas, Michael H. Ngo
-
Publication number: 20140011792Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.Type: ApplicationFiled: March 7, 2013Publication date: January 9, 2014Applicant: Umecrine ABInventors: Torbjörn Bäckström, Gianna Ragagnin
-
Publication number: 20140011793Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.Type: ApplicationFiled: March 7, 2013Publication date: January 9, 2014Applicant: Umecrine ABInventors: Torbjörn Bäckström, Gianna Ragagnin
-
Patent number: 8623849Abstract: Novel benzoic acid hydrazones of 5?-androstan-3,17-dione have been prepared on the basis of steroidal tigogenin of the plant Yucca gloriosa. The hydrazones of the General Formula (I), General Formula (II) and General Formula (III) as shown in the accompanying FIGURE of the drawing are synthesized. The hydrazones have shown promising anti-T.B., anti-cancer and anti-HIV activity revealing immense potential as more efficacious, less toxic drugs with fewer undesirable side effects. They could also prove valuable in correcting hormonal abnormalities that cause severe health problems.Type: GrantFiled: March 3, 2009Date of Patent: January 7, 2014Inventors: Ashok Ranganath Shelar, Maia Merlani, Milind Shelar, Lela Amiranashvili, Balkrishna Shelar
-
Patent number: 8623850Abstract: The invention relates to 15,16-methylene-17-(1?-propenyl)-17-3?-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the Z, R4, R6a, R6b, R7 and R18 have the meanings stated in claim 1, and solvates, hydrates and salts thereof, including all crystal modifications and all stereoisomers of these compounds. The invention also relates to the use of these derivatives for the production of a drug for oral contraception and for the treatment of pre-, peri- and postmenopausal problems and drugs which contain such derivatives, in particular use in the aforesaid indications. The derivatives according to the invention have a progestational and in preferable cases also an antimineralcorticoid and neutral to slight androgenic activity.Type: GrantFiled: December 23, 2008Date of Patent: January 7, 2014Assignee: Bayer Intellectual Property GmbHInventors: Ulrich Klar, Joachim Kuhnke, Rolf Bohlmann, Jan Hübner, Sven Ring, Thomas Frenzel, Frederik Menges, Steffen Borden, Hans-Peter Muhn, Katja Prelle
-
Publication number: 20140004206Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.Type: ApplicationFiled: June 13, 2013Publication date: January 2, 2014Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael S. Kolodney, Adam M. Rotunda
-
Publication number: 20140005156Abstract: Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament.Type: ApplicationFiled: August 28, 2013Publication date: January 2, 2014Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: MARC POIROT, PHILIPPE DE MEDINA, SANDRINE POIROT
-
Patent number: 8618087Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.Type: GrantFiled: December 19, 2012Date of Patent: December 31, 2013Assignee: Marinus PharmaceuticalsInventors: Kenneth Shaw, Mingbao Zhang
-
Publication number: 20130345188Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.Type: ApplicationFiled: June 17, 2013Publication date: December 26, 2013Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
-
Publication number: 20130338123Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H.R. Persicaner, Neda Irani, Julia M. AMADIO
-
Publication number: 20130338125Abstract: The invention provides and describes solid state 17?-ethynyl-5?-androstane-3?,17?-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-5?-androstane-3?,17?-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17?-ethynyl-5?-androstane-3?,17?-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-5?-androstane-3?,17?-diol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: June 17, 2013Publication date: December 19, 2013Inventors: Steven K. White, Dwight Stickney
-
Publication number: 20130337076Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.Type: ApplicationFiled: March 5, 2012Publication date: December 19, 2013Applicants: UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE, UNIVERSITE DE ROUENInventors: Ebba Brakenhielm, Sébastien Banquet, Florence Edwards-Levy, Christian Thuillez
-
Patent number: 8604011Abstract: In one aspect the present invention provides neuroactive steroids for use in the treatment of nervous system disorders, degenerative brain diseases and congenital storage diseases. In a second aspect the invention provides neuroactive steroids in combination with a Liver X Receptor (LXR) ligand to effect treatment of a nervous system condition.Type: GrantFiled: September 27, 2005Date of Patent: December 10, 2013Assignee: The Regents of the University of CaliforniaInventor: Synthia Mellon
-
Publication number: 20130324508Abstract: The present invention relates to a biomarker for characterizing prostate cancer and method of using the same. More particularly, the invention relates to method of using a membrane-associated C family G protein-coupled receptor GPRC6A as biomarker of characterizing prostate cancer progression. The present invention also provides a kit for detecting prostate cancer in a subject.Type: ApplicationFiled: June 3, 2013Publication date: December 5, 2013Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Leigh Darryl Quarles, Min Pi
-
Publication number: 20130323330Abstract: A method of treating prostate cancer by administering a pharmaceutically-acceptable amount of a crude extract of the indigenous Jamaican plant Ball Moss (Tillandsia Recurvata) comprising one or more cycloartane isolates, and the isolates used in the method for eliciting thereby a kinase inhibitory response of prostate cancer cells by selectively inhibiting MRCK? kinase and angiogenesis of (growth of new blood vessels) to reduce the viability of prostate cancer cells. The method and compounds holds promise as a chemopreventive agent, without causing excessive damage to normal cells.Type: ApplicationFiled: June 5, 2013Publication date: December 5, 2013Inventors: Henry Lowe, Joseph Bryant, DVM
-
Patent number: 8598149Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.Type: GrantFiled: August 27, 2008Date of Patent: December 3, 2013Assignee: Corcept Therapeutics, Inc.Inventor: Joseph K. Belanoff